Mylan Pharma Launches Generic Harvoni In India - Quick Facts

(RTTNews) - Mylan N.V. (MYL) announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched generic Harvoni (Ledipasvir 90 mg/Sofosbuvir 400 mg) tablets under the brand name MyHep LVIR in India. The Ledipasvir/Sofosbuvir combination is indicated for the treatment of Hepatitis C infection.

In September 2014, Mylan entered into a licensing and technology transfer agreement with Gilead granting Mylan the non-exclusive rights to manufacture and distribute generic Sofosbuvir and Ledipasvir/Sofosbuvir tablets in 101 developing countries, including India. The launch of MyHep LVIR follows the successful launch of generic Sofosbuvir in India under the brand name MyHep in April 2015.